Cytokine Release Syndrome - CRS General Review

Dr. Mohammad Sabbah

Abstract: Cytokine release syndrome-CRS is a systemic inflammatory response can progress to life threatening, resulting from generalized immune activation observed on day 2-7 after CAR-T cell infusion. The typical clinical mild symptoms presentations of CRS associated with flu-like symptoms, presented with high body fever as the first clinical symptom of CRS, including fatigue, headache, rash, arthralgia, and myalgia?s. The pathophysiology of CRS remains not understandable yet. What is known it is results from release massive of cytokines. CAR-T therapy considered as risk factor for sever CRS. Aggressive treatment should be given, including intensive monitoring. The typical symptomatic treatment of patients with severe CRS include tocilizumab, corticosteroids, vasoactive agents, organ protection treatment, antibiotics to prevent infections in neutropenic patients, transfusion support, volume resuscitation, and mechanical ventilation. The challenge knows is to understand the pathophysiology of CRS, this understanding can lead us to better control and minimizing the CRS symptoms.

Keywords: cytokine release syndrome, CAR-T, inflammatory response, immune activation, tocilizumab, corticosteroids

How to Cite?: Dr. Mohammad Sabbah, "Cytokine Release Syndrome - CRS General Review", Volume 12 Issue 9, September 2023, International Journal of Science and Research (IJSR), Pages: 1133-1134, https://www.ijsr.net/getabstract.php?paperid=SR23913033335, DOI: https://dx.doi.org/10.21275/SR23913033335